Cargando…
Interference-Free HER2 ECD as a Serum Biomarker in Breast Cancer
Over-expression of the HER2/neu receptor occurs in 20 to 30 percent of breast tumors and is linked to poorer prognosis. The HER2/neu expression status determines whether or not patient will receive trastuzumab-based treatment. In clinical practice, over-expression of HER2/neu is routinely identified...
Autores principales: | Lam, Lian, Czerniecki, Brian J., Fitzpatrick, Elizabeth, Xu, Shuwen, Schuchter, Lynn, Xu, Xiaowei, Zhang, Hongtao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4114390/ https://www.ncbi.nlm.nih.gov/pubmed/25089226 http://dx.doi.org/10.4172/2155-9929.1000151 |
Ejemplares similares
-
IL8 and Cathepsin B as Melanoma Serum Biomarkers
por: Zhang, Hongtao, et al.
Publicado: (2011) -
Relationships between serum HER2 ECD, TIMP-1 and clinical outcomes in Taiwanese breast cancer
por: Tsai, Hsiu-Pei, et al.
Publicado: (2012) -
Anti-HER2 CD4(+) T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancer
por: Datta, Jashodeep, et al.
Publicado: (2015) -
Monitoring serum HER2 levels in breast cancer patients
por: Tchou, Julia, et al.
Publicado: (2015) -
Murine Dendritic Cells Grown in Serum-Free Culture Show Potent Therapeutic Activity when Loaded with Novel Th Epitopes in an Orthotopic Model of HER2(pos) Breast Cancer
por: Showalter, Loral E., et al.
Publicado: (2021)